Tumor-Infiltrating Lymphocytes in Breast Cancer. Association with Clinical and Pathological Parameters

Заботина, Т. Н.; Короткова, О. В.; Черткова, А. И.; Захарова, Е. Н.; Tabakov, D; Dzhgamadze, N. Т.; Савостикова, М В; Артамонова, Е. В.; Хайленко, В. А.; Коваленко, Е. И.; Кадагидзе, З. Г.

doi:10.1007/s10517-018-4323-3

Cited by 6 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although differential cytokine patterns between the two groups are observed, these differences did not reach statistical significance, likely due to the wide inter-patient cytokine variability ( Figure S2). This apparently negative result does not exclude specific immunological interactions since TILs, that characterizes the ER(−) better than the ER(+) tumor tissue [28,42], could contribute to determine local specific interactions that can be better decoded by the circulatory metabolomics profiles.…”

Section: Discussionmentioning

confidence: 96%

Effect of Estrogen Receptor Status on Circulatory Immune and Metabolomics Profiles of HER2-Positive Breast Cancer Patients Enrolled for Neoadjuvant Targeted Chemotherapy

Vignoli

Muraro

Miolo

et al. 2020

Cancers

View full text Add to dashboard Cite

HER2-positive breast cancer (BC) represents a heterogeneous cancer disease. In an attempt to identify new stratification models useful for prognosis and therapeutic strategy, we investigated the influence of estrogen receptor (ER) status on the host immune and metabolomics profile of HER2-positive BC patients enrolled for neoadjuvant targeted chemotherapy (NATC). The study enrolled 43 HER2-positive BC patients eligible for NATC based on the trastuzumab-paclitaxel combination. Baseline circulatory cytokines and 1H NMR plasma metabolomics profiles were investigated. Differences in the immune cytokines and metabolomics profile as a function of the ER status, and their association with clinical outcomes were studied by multivariate and univariate analysis. Baseline metabolomics profiles were found to discriminate HER2-positive ER(+) from ER(−) BC patients. Within the ER(+) group an immune-metabolomics model, based on TNF-α and valine, predicted pathological complete response to NATC with 90.9% accuracy (AUROC = 0.92, p = 0.004). Moreover, metabolomics information integrated with IL-2 and IL-10 cytokine levels were prognostic of relapse with an accuracy of 95.5%. The results indicate that in HER2-positive BC patients the ER status influences the host circulatory immune-metabolomics profile. The baseline immune-metabolomics assessment in combination with ER status could represent an independent stratification tool able to predict NATC response and disease relapse of HER2-positive patients.

show abstract

Section: Discussionmentioning

confidence: 96%

Effect of Estrogen Receptor Status on Circulatory Immune and Metabolomics Profiles of HER2-Positive Breast Cancer Patients Enrolled for Neoadjuvant Targeted Chemotherapy

Vignoli

Muraro

Miolo

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…Neutrophils can stimulate the production of chemokines and cytokines which change the tumor microenvironment, facilitate angiogenesis , in uence the antitumor immune effects and promote tumor cells to proliferation and migration [9,34]. Lymphocytes play a role in the immune surveillance and the control of tumor growth by natural killer T cell and activated T cell [10,35].Recently many in ammatory immune ratios based on peripheral in ammatory cells, such as NLR,PLR and LMR, were used to predict the prognosis of various tumor [13,36,37]. Kim EY et al veri ed that high preoperative and postoperative NLR were associated with poorer survival rates in patients with gastric cancer [38].…”

Section: Resultsmentioning

confidence: 99%

Inflammation-based Neutrophil-to-Lymphocyte Ratio(NLR) as a Prognostic Biomarker for Patients With High-Risk Neuroblastoma

Wang

Zhou

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Neutrophil-to-lymphocyte ratio (NLR) has been proven to be a prognostic biomarker in many malignancies. However, the prognostic significance of NLR in patients with high-risk neuroblastoma has not been reported. This study aims to evaluate the correlation between NLR and prognosis of patients with high-risk neuroblastoma.Methods: We retrospectively analysed a cohort of 41 patients with high-risk neuroblastoma between January 2011 and December 2020. The optimal cut-off points of prognostic biomarkers were determined by drawing receiver operating characteristic (ROC) curves. According to the cut-off value, the patients were divided into low NLR group and high NLR group. The chi-square test was used to compare the clinicopathological parameters between the two NLR groups. The prognostic value of NLR was assessed using the Kaplan-Meier and univariable and multivariable Cox models.Results: Patients with high NLR were significantly related to poorer clinical characteristics and survival rate in high-risk subgroup neuroblastoma. In the univariate and multivariate Cox analyses, high NLR was an independent prognostic factor for patients with high-risk neuroblastoma (hazard ratio (HR) 5.066, 95% confidence interval (CI): 1.303-19.699, P=0.019 ).Conclusions: Our study demonstrated that NLR was an independent prognostic biomarker for high-risk neuroblastoma. As NLR is easily calculated by widely available tests without additional costs, it can help guide subsequent therapeutic strategies for patients with high-risk neuroblastoma.

show abstract

“…CD16+ lymphocytes inversely correlated with the proportion of regulatory CD4+CD25+CD127- cells and the Ki-67 rate in tumour cells. Accordingly, a higher level of Ki-67 occurred concomitantly with decreased effector lymphocytes (CD8+ and CD16+) and a high percentage of regulatory CD8+CD11b-CD28- T cells ( 34 ). In addition, oncogenic pathway alterations are likely to play a crucial role in T cell cutting out or the inhibition of T cell activity ( 21 ).…”

Section: Experimental Findings On Tumour Growth And/or Immune Evasion...mentioning

confidence: 99%

Experimental and clinical evidence in favour of an effective immune stimulation in ER-positive, endocrine-dependent metastatic breast cancer

Nicolini,

Rossi,

Ferrari

2024

Front. Immunol.

View full text Add to dashboard Cite

In ER+ breast cancer, usually seen as the low immunogenic type, the main mechanisms favouring the immune response or tumour growth and immune evasion in the tumour microenvironment (TME) have been examined. The principal implications of targeting the oestrogen-mediated pathways were also considered. Recent experimental findings point out that anti-oestrogens contribute to the reversion of the immunosuppressive TME. Moreover, some preliminary clinical data with the hormone-immunotherapy association in a metastatic setting support the notion that the reversion of immune suppression in TME is likely favoured by the G0-G1 state induced by anti-oestrogens. Following immune stimulation, the reverted immune suppression allows the boosting of the effector cells of the innate and adaptive immune response. This suggests that ER+ breast cancer is a molecular subtype where a successful active immune manipulation can be attained. If this is confirmed by a prospective multicentre trial, which is expected in light of the provided evidence, the proposed hormone immunotherapy can also be tested in the adjuvant setting. Furthermore, the different rationale suggests a synergistic activity of our proposed immunotherapy with the currently recommended regimen consisting of antioestrogens combined with cyclin kinase inhibitors. Overall, this lays the foundation for a shift in clinical practice within this most prevalent molecular subtype of breast cancer.

show abstract

Tumor-Infiltrating Lymphocytes in Breast Cancer. Association with Clinical and Pathological Parameters

Cited by 6 publications

References 9 publications

Effect of Estrogen Receptor Status on Circulatory Immune and Metabolomics Profiles of HER2-Positive Breast Cancer Patients Enrolled for Neoadjuvant Targeted Chemotherapy

Effect of Estrogen Receptor Status on Circulatory Immune and Metabolomics Profiles of HER2-Positive Breast Cancer Patients Enrolled for Neoadjuvant Targeted Chemotherapy

Inflammation-based Neutrophil-to-Lymphocyte Ratio(NLR) as a Prognostic Biomarker for Patients With High-Risk Neuroblastoma

Experimental and clinical evidence in favour of an effective immune stimulation in ER-positive, endocrine-dependent metastatic breast cancer

Contact Info

Product

Resources

About